Laigo Bio

Seed
laigobio.com Biotech & Healthcare Utrecht, The Netherlands
Total Funding $19.7M
Latest Round $19.7M Seed
Last Announced Mar 23, 2026
Investors Undisclosed
Decision Makers 6 Verified

About Laigo Bio

Laigo Bio uses E3 ligase internalization to precisely degrade membrane proteins linked to autoimmune and inflammatory disorders.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Seed
Global Headquarters Utrecht, The Netherlands
Tracked Since Oct 2, 2026

Web & Domain Identity

Official Website laigobio.com
Domain Registered Date Dec 1, 2021

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Company Profile

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Raised $19,700,000 · Seed

    news.google.com

  2. Milestone

    Website domain registered

    laigobio.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Laigo Bio.

Funding History

1 Round
Seed equity · Mar 23, 2026
$19,700,000 news.google.com

Founders & Leadership

2

Madelon Maurice

Scientific founder

Work email & phone locked Unlock →

Neill Moray Mackenzie

Co-founder & Chair

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts